Patent: 6,017,897
✉ Email this page to a colleague
Summary for Patent: 6,017,897
Title: | Nucleic acid respiratory syncytial virus vaccines |
Abstract: | Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample. |
Inventor(s): | Li; Xiaomao (Thornhill, CA), Ewasyshyn; Mary E. (Willowdale, CA), Sambhara; Suryaprakash (Markham, CA), Klein; Michel H. (Willowdale, CA) |
Assignee: | Pasteur Merieux Connaught Canada (Ontario, CA) |
Application Number: | 08/896,500 |
Patent Claims: | see list of patent claims |
Details for Patent 6,017,897
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2015-06-07 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2015-06-07 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2015-06-07 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |